Description: Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
Home Page: upstreambio.com
890 Winter Street
Waltham,
MA
02451
United States
Phone:
781 208 2466
Officers
| Name | Title |
|---|---|
| Mr. Aaron Deykin M.D. | Chief Medical Officer and Head of Research & Development |
| Dr. E. Rand Sutherland M.D., M.P.H., MPH | CEO & Director |
| Mr. Michael Paul Gray CPA, MBA | CFO & COO |
| Ms. Parika Petaipimol M.S. | Head of Technical Operations |
| Ms. Lisa Fiering | Senior Vice President of People & Culture |
| Dr. Adam Houghton M.B.A., Ph.D. | Chief Business Officer |
| Ms. Mersedeh Miraliakbari Pharm.D. | Senior Vice President of Regulatory Affairs & Quality |
| Ms. Fang Xie Ph.D. | VP & Head of Biometrics |
| Dr. Sumathi Sivapalasingam M.D. | VP & Head of Clinical Development |
| Ms. Maryse Courval M.S. | VP & Head of Clinical Operations |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2024-10-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |